World leader in diabetes care products, Novo Nordisk today announced the availability of a 'basal insulin analogue' Levermir in India, which is aimed at controlling blood sugar levels in people suffering the disease.


The novel diabetes therapy, for people with types I and II diabetes, would be available in the country from Friday, the company said in a statement here.


Levemir, a long-acting insulin analogue for the treatment of diabetes, provides predictable abd consistent control of blood glucose levels. As a result, blood glucose levels are maintained within a very narrow range especially during the night, the company said.


The drug, also available with a device that is simple and easy to use, provides flexibility and convenience for people with diabetes, it said.

"Availability of Levemir makes Novo Nordisk the first company in India to have short and long acting insulin analogue for adults and children thereby showing our commitment to treating and defeating diabetes here,"

said the Managing Director of Novo Nord isk India Pvt Ltd, Mr Melvin Oscar D'Souza here.


The company said it plans to send a team trained on Levemir to about 30,000 doctors in diabetes clinics, primary healthcare centres and pharmacists throughout the country to explain the best practices in insulin therapy.


Source: The Hindu Business Line